Neoadjuvant Intratumoral Immunotherapy with Cowpea Mosaic Virus Induces Local and Systemic Antitumor Efficacy in Canine Mammary Cancer Patients.
canine mammary cancer
cowpea mosaic virus
immune cells
intratumoral immunotherapy
nanoparticles
patient outcome
plant virus
tumor microenvironment
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
08 09 2023
08 09 2023
Historique:
received:
17
08
2023
revised:
04
09
2023
accepted:
06
09
2023
medline:
29
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
The lack of optimal models to evaluate novel agents is delaying the development of effective immunotherapies against human breast cancer (BC). In this prospective open label study, we applied neoadjuvant intratumoral immunotherapy with empty cowpea mosaic virus-like particles (eCPMV) to 11 companion dogs diagnosed with canine mammary cancer (CMC), a spontaneous tumor resembling human BC. We found that two neoadjuvant intratumoral eCPMV injections resulted in tumor reduction in injected tumors in all patients and in noninjected tumors located in the ipsilateral and contralateral mammary chains of injected dogs. Tumor reduction was independent of clinical stage, tumor size, histopathologic grade, and tumor molecular subtype. RNA-seq-based analysis of injected tumors indicated a decrease in DNA replication activity and an increase in activated dendritic cell infiltration in the tumor microenvironment. Immunohistochemistry analysis demonstrated significant intratumoral increases in neutrophils, T and B lymphocytes, and plasma cells. eCPMV intratumoral immunotherapy demonstrated antitumor efficacy without any adverse effects. This novel immunotherapy has the potential for improving outcomes for human BC patients.
Identifiants
pubmed: 37759464
pii: cells12182241
doi: 10.3390/cells12182241
pmc: PMC10527658
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : U01 CA218292
Pays : United States
Organisme : NIH HHS
ID : S10 OD030242
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM130454
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA023108
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA224605
Pays : United States
Références
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
Breast Cancer Res Treat. 2003 Mar;78(2):141-8
pubmed: 12725414
J Clin Oncol. 2010 Apr 10;28(11):1821-8
pubmed: 20231683
Cancers (Basel). 2019 Apr 10;11(4):
pubmed: 30974896
Nat Nanotechnol. 2016 Mar;11(3):295-303
pubmed: 26689376
Philos Trans R Soc Lond B Biol Sci. 2015 Jul 19;370(1673):
pubmed: 26056372
Biomaterials. 2021 Aug;275:120914
pubmed: 34126409
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Blood. 2010 Jan 14;115(2):335-43
pubmed: 19890092
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
ACS Nano. 2020 Mar 24;14(3):2994-3003
pubmed: 32133838
Vet Comp Oncol. 2021 Jun;19(2):311-352
pubmed: 33427378
Ann Oncol. 2018 Nov 1;29(11):2163-2174
pubmed: 30295695
J Virol. 2019 Oct 15;93(21):
pubmed: 31375592
Clin Cancer Res. 2018 Feb 1;24(3):511-520
pubmed: 28801472
Vet Comp Oncol. 2009 Sep;7(3):162-72
pubmed: 19691645
Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
J Small Anim Pract. 2000 Jul;41(7):287-91
pubmed: 10976622
Immunology. 2020 Feb;159(2):183-192
pubmed: 31630392
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Int Immunopharmacol. 2013 Nov;17(3):638-50
pubmed: 23994464
Oncotarget. 2015 Oct 13;6(31):31820-9
pubmed: 26378809
J Reprod Fertil Suppl. 2001;57:439-43
pubmed: 11787188
Semin Oncol. 2017 Aug;44(4):288-300
pubmed: 29526258
Vet Sci. 2022 Mar 31;9(4):
pubmed: 35448665
Adv Funct Mater. 2020 Jul 2;30(27):
pubmed: 34366758
PLoS One. 2019 Jul 3;14(7):e0219214
pubmed: 31269060
Front Vet Sci. 2021 Feb 17;8:623800
pubmed: 33681329
Lancet. 2020 Dec 5;396(10265):1817-1828
pubmed: 33278935
Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):809-815
pubmed: 28522448
J Natl Cancer Inst. 2018 Aug 1;110(8):803-811
pubmed: 29873743
J Biol Chem. 1994 Jun 3;269(22):15918-24
pubmed: 8195247
Vet Pathol. 2016 Nov;53(6):1138-1146
pubmed: 27162119
J Clin Oncol. 2020 Aug 10;38(23):2667-2676
pubmed: 32552274
Genome Res. 2020 Dec 23;:
pubmed: 33361113
Nat Immunol. 2011 Dec 25;13(2):170-80
pubmed: 22197976
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35277459
Mol Pharm. 2018 Sep 4;15(9):3717-3722
pubmed: 29613803
Annu Rev Pathol. 2011;6:95-119
pubmed: 20936938
Cancer. 2013 Mar 15;119(6):1140-8
pubmed: 23065954
Vet Pathol. 2014 Jan;51(1):127-45
pubmed: 24227007
Vet Pathol. 2013 Jan;50(1):94-105
pubmed: 22688585
Genome Biol. 2010;11(10):R106
pubmed: 20979621
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Eur J Pharmacol. 2013 Oct 5;717(1-3):58-66
pubmed: 23545358
Virology. 2009 Oct 25;393(2):329-37
pubmed: 19733890
Immunol Lett. 2022 Jul;247:52-58
pubmed: 35577002
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
JAMA. 2019 Jan 22;321(3):288-300
pubmed: 30667505
J Exp Med. 1991 Nov 1;174(5):1209-20
pubmed: 1940799
J Immunother Cancer. 2022 Dec;10(12):
pubmed: 36460333
Cytometry A. 2020 Oct;97(10):1024-1027
pubmed: 32583607
Front Immunol. 2020 Jan 17;10:2935
pubmed: 32010120
ACS Nano. 2022 Nov 22;16(11):18315-18328
pubmed: 36264973
J Immunother Cancer. 2019 Apr 15;7(1):105
pubmed: 30992085
Nat Med. 2023 Mar;29(3):646-655
pubmed: 36879128
PLoS Biol. 2020 Jul 14;18(7):e3000410
pubmed: 32663219
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Adv Sci (Weinh). 2019 Jun 19;6(16):1802281
pubmed: 31453050
Animals (Basel). 2020 Sep 18;10(9):
pubmed: 32961915
J Am Vet Med Assoc. 2001 Oct 15;219(8):1110-4
pubmed: 11700710
Front Immunol. 2014 Oct 21;5:508
pubmed: 25374568
Vet Comp Oncol. 2011 Sep;9(3):172-82
pubmed: 21848620